Abstract: A therapeutic combination of drugs for the treatment of a liver cancer includes a crocin, or a pharmaceutically acceptable pro-drug thereof, and sorafenib. A method of treating, suppressing, or reducing the severity of a liver cancer in a subject, involves administering to the subject a first amount of sorafenib, and administering to the subject a second amount of a crocin or a pharmaceutically acceptable pro-drug thereof.

Abstract: Methods of preventing the formation of liver cancer in a subject are described herein. In the disclosed methods, a prophylactically effective amount of safranal may be administered to a subject. In some embodiments, the subject may suffer from hepatic oxidative stress and/or hepatic inflammation. In another aspect, methods of preventing the formation of a liver cancer in a subject are disclosed that include monitoring the level of a liver cancer marker and administering a prophylactically effective amount of safranal to the subject, such that the effective amount is effective to maintain a normal level of the liver cancer marker.

Abstract: A therapeutic combination of drugs for the treatment of a liver cancer includes a crocin, or a pharmaceutically acceptable pro-drug thereof, and sorafenib. A method of treating, suppressing, or reducing the severity of a liver cancer in a subject, involves administering to the subject a first amount of sorafenib, and administering to the subject a second amount of a crocin or a pharmaceutically acceptable pro-drug thereof.

Abstract: Methods of preventing the formation of liver cancer in a subject are described herein. In the disclosed methods, a prophylactically effective amount of safranal may be administered to a subject. In some embodiments, the subject may suffer from hepatic oxidative stress and/or hepatic inflammation. In another aspect, methods of preventing the formation of a liver cancer in a subject are disclosed that include monitoring the level of a liver cancer marker and administering a prophylactically effective amount of safranal to the subject, such that the effective amount is effective to maintain a normal level of the liver cancer marker.

Abstract: Methods of treating, suppressing, or reducing the severity of a liver cancer in a subject are described herein. The disclosed methods include administering to the subject a first amount of safranal or a pharmaceutically acceptable pro-drug thereof and administering to the subject a second amount of a TOP1 inhibitor. In some embodiments, the TOP1 inhibitor is irinotecan, topotecan, camptothecin, lamellarin D, and/or combinations thereof.

Abstract: A method of treating, suppressing, or reducing the severity of hyperproliferative disease, includes the administration of a therapeutically effective amount of a composition having safranal to a subject with a hyperproliferative disease in which Cdc25B is over-expressed. The hyperproliferative disease may be a benign tumor or a malignant tumor. The therapeutically effective amount may be administered orally or parenterally. In representative embodiments, the amount of safranal may be from about 10 mg/day to about 1000 mg/day per kg body weight of the subject.

Abstract: Methods of treating, suppressing, or reducing the severity of a liver cancer in a subject are described herein. The disclosed methods involve administering a therapeutically effective amount of a composition including safranal or its pharmaceutically acceptable pro-drug, and a pharmaceutically acceptable carrier to the subject. The disclosed methods may be used to treat, suppress, or reduce the severity of various liver cancers, including hepatocellular carcinoma (HCC), fibrolamellar HCC, cholangiocarcinoma, angiosarcoma, a metastatic liver cancer, and combinations thereof.

Abstract: A therapeutic combination of drugs for the treatment of a liver cancer includes safranal or a pharmaceutically acceptable pro-drug thereof, and sorafenib. In representative embodiments, the pro-drug is selected from the group of a safranal salt, hydrate, hemiacetal, acetal, thioacetal, silylether, tautomer, isomer, and combinations thereof. The safranal and the sorafenib may be compounded together in a same unitary pharmaceutical composition including both compounds. Alternatively, the safranal and the sorafenib may be provided in the form of separate pharmaceutical compositions.

Abstract: A low-power high-swing current-mode logic (CML) driver circuit includes a first differential-pair and a second differential-pair. The first differential-pair includes first transistors, and is coupled to a first voltage supply that supplies a first voltage. The second differential-pair includes second transistors, and a common node of the second differential-pair is coupled to a second voltage supply. The second voltage supply supplies a second voltage that is higher than the first voltage. Control terminals of the first transistors are coupled to control terminals of the second transistors to form input nodes of the driver circuit.